<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240330021025&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240330021025&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 30 Mar 2024 06:10:27 +0000</lastbuilddate>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: Tricuspid valve disease and cardiac implantable electronic devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38552211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae221. doi: 10.1093/eurheartj/ehae221. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38552211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38552211</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae221>10.1093/eurheartj/ehae221</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38552211</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Tricuspid valve disease and cardiac implantable electronic devices</dc:title>
<dc:identifier>pmid:38552211</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae221</dc:identifier>
</item>
<item>
<title>Correction to: Changes in frailty and incident cardiovascular disease in three prospective cohorts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38552139/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae175. doi: 10.1093/eurheartj/ehae175. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38552139/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38552139</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae175>10.1093/eurheartj/ehae175</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38552139</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Changes in frailty and incident cardiovascular disease in three prospective cohorts</dc:title>
<dc:identifier>pmid:38552139</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae175</dc:identifier>
</item>
<item>
<title>Management of heart failure in Mexico: challenges and opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38551512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093/eurheartj/ehae059. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38551512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38551512</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae059>10.1093/eurheartj/ehae059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38551512</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Antonio Alcocer-Gamba</dc:creator>
<dc:creator>Amada Álvarez-Sangabriel</dc:creator>
<dc:creator>José Antonio de la Parra-Calderón</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Management of heart failure in Mexico: challenges and opportunities</dc:title>
<dc:identifier>pmid:38551512</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae059</dc:identifier>
</item>
<item>
<title>Patient-physician sex concordance and outcomes in cardiovascular disease: a systematic review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38551446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>The sex disparity in outcomes of patients with cardiovascular disease is well-described and has persisted across recent decades. While there have been several proposed mechanisms to explain this disparity, there are limited data on female patient-physician sex concordance and its association with outcomes. The authors review the existing literature on the relationship between patient-physician sex concordance and clinical outcomes in patients with cardiovascular disease, the evidence of a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae121. doi: 10.1093/eurheartj/ehae121. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The sex disparity in outcomes of patients with cardiovascular disease is well-described and has persisted across recent decades. While there have been several proposed mechanisms to explain this disparity, there are limited data on female patient-physician sex concordance and its association with outcomes. The authors review the existing literature on the relationship between patient-physician sex concordance and clinical outcomes in patients with cardiovascular disease, the evidence of a benefit in clinical outcomes with female patient-physician sex concordance, and the possible drivers of such a benefit and highlight directions for future study.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38551446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38551446</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae121>10.1093/eurheartj/ehae121</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38551446</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Ko Yamamoto</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Lisa Q Rong</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>C Noel Bairey-Merz</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Patient-physician sex concordance and outcomes in cardiovascular disease: a systematic review</dc:title>
<dc:identifier>pmid:38551446</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae121</dc:identifier>
</item>
<item>
<title>Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38551411/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates that absolute CVD risk, determined by a clinical risk score, and relative genetic risk, determined by a PRS, provide independent information. The two components may form a simple multiplicative model improving precision of guideline-recommended tools in predicting incident CVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae048. doi: 10.1093/eurheartj/ehae048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: It is not clear how a polygenic risk score (PRS) can be best combined with guideline-recommended tools for cardiovascular disease (CVD) risk prediction, e.g. SCORE2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A PRS for coronary artery disease (CAD) was calculated in participants of UK Biobank (n = 432 981). Within each tenth of the PRS distribution, the odds ratios (ORs)-referred to as PRS-factor-for CVD (i.e. CAD or stroke) were compared between the entire population and subgroups representing the spectrum of clinical risk. Replication was performed in the combined Framingham/Atherosclerosis Risk in Communities (ARIC) populations (n = 10 757). The clinical suitability of a multiplicative model 'SCORE2 × PRS-factor' was tested by risk reclassification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In subgroups with highly different clinical risks, CVD ORs were stable within each PRS tenth. SCORE2 and PRS showed no significant interactive effects on CVD risk, which qualified them as multiplicative factors: SCORE2 × PRS-factor = total risk. In UK Biobank, the multiplicative model moved 9.55% of the intermediate (n = 145 337) to high-risk group increasing the individuals in this category by 56.6%. Incident CVD occurred in 8.08% of individuals reclassified by the PRS-factor from intermediate to high risk, which was about two-fold of those remained at intermediate risk (4.08%). Likewise, the PRS-factor shifted 8.29% of individuals from moderate to high risk in Framingham/ARIC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates that absolute CVD risk, determined by a clinical risk score, and relative genetic risk, determined by a PRS, provide independent information. The two components may form a simple multiplicative model improving precision of guideline-recommended tools in predicting incident CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38551411/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38551411</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae048>10.1093/eurheartj/ehae048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38551411</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ling Li</dc:creator>
<dc:creator>Shichao Pang</dc:creator>
<dc:creator>Fabian Starnecker</dc:creator>
<dc:creator>Bertram Mueller-Myhsok</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease</dc:title>
<dc:identifier>pmid:38551411</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae048</dc:identifier>
</item>
<item>
<title>LuX-Valve Plus transcatheter tricuspid valve replacement for massive tricuspid flail after lead extraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38551409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 29:ehae165. doi: 10.1093/eurheartj/ehae165. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38551409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38551409</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae165>10.1093/eurheartj/ehae165</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38551409</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Shahrukh N Bakar</dc:creator>
<dc:creator>Geraldine Ong</dc:creator>
<dc:creator>Neil P Fam</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>LuX-Valve Plus transcatheter tricuspid valve replacement for massive tricuspid flail after lead extraction</dc:title>
<dc:identifier>pmid:38551409</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae165</dc:identifier>
</item>
<item>
<title>A newly identified gut hormone suppresses cholesterol production in the liver</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38548956/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 28. doi: 10.1038/s41569-024-01021-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38548956/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38548956</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01021-1>10.1038/s41569-024-01021-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38548956</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>A newly identified gut hormone suppresses cholesterol production in the liver</dc:title>
<dc:identifier>pmid:38548956</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01021-1</dc:identifier>
</item>
<item>
<title>Correction to: Prednisone administration in inflammatory cardiomyopathy: caveat for potentially adverse myocardial actions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae219. doi: 10.1093/eurheartj/ehae219. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547459</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae219>10.1093/eurheartj/ehae219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547459</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Prednisone administration in inflammatory cardiomyopathy: caveat for potentially adverse myocardial actions</dc:title>
<dc:identifier>pmid:38547459</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae219</dc:identifier>
</item>
<item>
<title>Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093/eurheartj/ehae167. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547456</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae167>10.1093/eurheartj/ehae167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547456</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction</dc:title>
<dc:identifier>pmid:38547456</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae167</dc:identifier>
</item>
<item>
<title>Sorbs2 Modulation of BK Channels in Arterial Myocytes: Implications for Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):872-874. doi: 10.1161/CIRCRESAHA.124.324241. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547252</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324241>10.1161/CIRCRESAHA.124.324241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547252</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>L Fernando Santana</dc:creator>
<dc:creator>Manuel F Navedo</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Sorbs2 Modulation of BK Channels in Arterial Myocytes: Implications for Diabetes</dc:title>
<dc:identifier>pmid:38547252</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324241</dc:identifier>
</item>
<item>
<title>Biological Pacemakers: Present and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):837-841. doi: 10.1161/CIRCRESAHA.123.323180. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547251</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323180>10.1161/CIRCRESAHA.123.323180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547251</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Thassio Mesquita</dc:creator>
<dc:creator>Rodrigo Miguel-Dos-Santos</dc:creator>
<dc:creator>Eugenio Cingolani</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Biological Pacemakers: Present and Future</dc:title>
<dc:identifier>pmid:38547251</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323180</dc:identifier>
</item>
<item>
<title>Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>The ECM (extracellular matrix) is a major component of the vascular microenvironment that modulates vascular homeostasis. ECM proteins include collagens, elastin, noncollagen glycoproteins, and proteoglycans/glycosaminoglycans. ECM proteins form complex matrix structures, such as the basal lamina and collagen and elastin fibers, through direct interactions or lysyl oxidase-mediated cross-linking. Moreover, ECM proteins directly interact with cell surface receptors or extracellular secreted...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):931-949. doi: 10.1161/CIRCRESAHA.123.324055. Epub 2024 Mar 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ECM (extracellular matrix) is a major component of the vascular microenvironment that modulates vascular homeostasis. ECM proteins include collagens, elastin, noncollagen glycoproteins, and proteoglycans/glycosaminoglycans. ECM proteins form complex matrix structures, such as the basal lamina and collagen and elastin fibers, through direct interactions or lysyl oxidase-mediated cross-linking. Moreover, ECM proteins directly interact with cell surface receptors or extracellular secreted molecules, exerting matricellular and matricrine modulation, respectively. In addition, extracellular proteases degrade or cleave matrix proteins, thereby contributing to ECM turnover. These interactions constitute the ECM interactome network, which is essential for maintaining vascular homeostasis and preventing pathological vascular remodeling. The current review mainly focuses on endogenous matrix proteins in blood vessels and discusses the interaction of these matrix proteins with other ECM proteins, cell surface receptors, cytokines, complement and coagulation factors, and their potential roles in maintaining vascular homeostasis and preventing pathological remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547250</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324055>10.1161/CIRCRESAHA.123.324055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547250</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Fu</dc:creator>
<dc:creator>Yuan Zhou</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Zhuofan Li</dc:creator>
<dc:creator>Wei Kong</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling</dc:title>
<dc:identifier>pmid:38547250</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324055</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):834-836. doi: 10.1161/RES.0000000000000667. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547249</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000667>10.1161/RES.0000000000000667</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547249</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38547249</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000667</dc:identifier>
</item>
<item>
<title>Untangling Complexity: Gut Microbiota, Metabolites, and Fiber Intake in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):855-857. doi: 10.1161/CIRCRESAHA.124.324333. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547248</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324333>10.1161/CIRCRESAHA.124.324333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547248</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Nathan T Greenberg</dc:creator>
<dc:creator>Vienna E Brunt</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Untangling Complexity: Gut Microbiota, Metabolites, and Fiber Intake in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38547248</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324333</dc:identifier>
</item>
<item>
<title>Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among United States Hispanics/Latinos, dietary fiber intake was associated with favorable profiles of gut microbiota and circulating metabolites for T2D. These findings advance our understanding of the role of gut microbiota and microbial metabolites in the relationship between diet and T2D.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):842-854. doi: 10.1161/CIRCRESAHA.123.323634. Epub 2024 Mar 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Consistent evidence suggests diabetes-protective effects of dietary fiber intake. However, the underlying mechanisms, particularly the role of gut microbiota and host circulating metabolites, are not fully understood. We aimed to investigate gut microbiota and circulating metabolites associated with dietary fiber intake and their relationships with type 2 diabetes (T2D).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study included up to 11 394 participants from the HCHS/SOL (Hispanic Community Health Study/Study of Latinos). Diet was assessed with two 24-hour dietary recalls at baseline. We examined associations of dietary fiber intake with gut microbiome measured by shotgun metagenomics (350 species/85 genera and 1958 enzymes; n=2992 at visit 2), serum metabolome measured by untargeted metabolomics (624 metabolites; n=6198 at baseline), and associations between fiber-related gut bacteria and metabolites (n=804 at visit 2). We examined prospective associations of serum microbial-associated metabolites (n=3579 at baseline) with incident T2D over 6 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified multiple bacterial genera, species, and related enzymes associated with fiber intake. Several bacteria (eg, <i>Butyrivibrio</i>, <i>Faecalibacterium</i>) and enzymes involved in fiber degradation (eg, xylanase EC3.2.1.156) were positively associated with fiber intake, inversely associated with prevalent T2D, and favorably associated with T2D-related metabolic traits. We identified 159 metabolites associated with fiber intake, 47 of which were associated with incident T2D. We identified 18 of these 47 metabolites associated with the identified fiber-related bacteria, including several microbial metabolites (eg, indolepropionate and 3-phenylpropionate) inversely associated with the risk of T2D. Both <i>Butyrivibrio</i> and <i>Faecalibacterium</i> were associated with these favorable metabolites. The associations of fiber-related bacteria, especially <i>Faecalibacterium</i> and <i>Butyrivibrio</i>, with T2D were attenuated after further adjustment for these microbial metabolites.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among United States Hispanics/Latinos, dietary fiber intake was associated with favorable profiles of gut microbiota and circulating metabolites for T2D. These findings advance our understanding of the role of gut microbiota and microbial metabolites in the relationship between diet and T2D.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38547246</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323634>10.1161/CIRCRESAHA.123.323634</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547246</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zheng Wang</dc:creator>
<dc:creator>Brandilyn A Peters</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Megan L Grove</dc:creator>
<dc:creator>Tao Wang</dc:creator>
<dc:creator>Xiaonan Xue</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Gang Hu</dc:creator>
<dc:creator>Yasmin Mossavar-Rahmani</dc:creator>
<dc:creator>Carmen R Isasi</dc:creator>
<dc:creator>Rob Knight</dc:creator>
<dc:creator>Robert D Burk</dc:creator>
<dc:creator>Robert C Kaplan</dc:creator>
<dc:creator>Qibin Qi</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38547246</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323634</dc:identifier>
</item>
<item>
<title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae025. doi: 10.1093/eurheartj/ehae025. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38546417</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae025>10.1093/eurheartj/ehae025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546417</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria Grazia Bongiorni</dc:creator>
<dc:creator>Giulio Zucchelli</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</dc:title>
<dc:identifier>pmid:38546417</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae025</dc:identifier>
</item>
<item>
<title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae127. doi: 10.1093/eurheartj/ehae127. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a single-centre, retrospective, cohort analysis including consecutive ICD/CRT-D patients implanted between 2012 and 2021. These patients were screened against a list of all hospitalized patients having positive blood cultures consistent with diagnosed infection in any department of a local public hospital.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The total cohort consisted of 515 patients. Over a median follow-up of 59 months (interquartile range 31-87 months), there were 47 BSI episodes in 36 patients. The majority of patients with BSI (92%) was admitted to non-cardiology units, and in 25 episodes (53%), no cardiac imaging was performed. Nearly all patients (85%) were treated with short-term antibiotics, whereas chronic antibiotic suppression therapy (n = 4) and system extraction (n = 3) were less frequent. Patients with BSI had a nearly seven-fold higher rate (hazard ratio 6.7, 95% confidence interval 3.9-11.2; P &lt; .001) of all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38546408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae127>10.1093/eurheartj/ehae127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546408</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Tardu Özkartal</dc:creator>
<dc:creator>Andrea Demarchi</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Damiano Pongan</dc:creator>
<dc:creator>Catherine Klersy</dc:creator>
<dc:creator>Maria Luce Caputo</dc:creator>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Enos Bernasconi</dc:creator>
<dc:creator>Valeria Gaia</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</dc:title>
<dc:identifier>pmid:38546408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae127</dc:identifier>
</item>
<item>
<title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 28. doi: 10.1161/CIR.0000000000001225. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science advisory reviews the use of wearables in patients with congenital heart disease, how to improve these technologies for clinicians and patients, and ethical and regulatory considerations. Challenges related to the use of wearables are common to every clinical setting, but specific topics for consideration in congenital heart disease are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38545775</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001225>10.1161/CIR.0000000000001225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38545775</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Animesh Tandon</dc:creator>
<dc:creator>Jennifer N Avari Silva</dc:creator>
<dc:creator>Ami B Bhatt</dc:creator>
<dc:creator>Colin K Drummond</dc:creator>
<dc:creator>Allison C Hill</dc:creator>
<dc:creator>Amanda E Paluch</dc:creator>
<dc:creator>Sheradon Waits</dc:creator>
<dc:creator>Jenny E Zablah</dc:creator>
<dc:creator>Kevin C Harris</dc:creator>
<dc:creator>Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38545775</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001225</dc:identifier>
</item>
<item>
<title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae158. doi: 10.1093/eurheartj/ehae158. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Built environment plays an important role in the development of cardiovascular disease. Tools to evaluate the built environment using machine vision and informatic approaches have been limited. This study aimed to investigate the association between machine vision-based built environment and prevalence of cardiometabolic disease in US cities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cross-sectional study used features extracted from Google Street View (GSV) images to measure the built environment and link them with prevalence of coronary heart disease (CHD). Convolutional neural networks, linear mixed-effects models, and activation maps were utilized to predict health outcomes and identify feature associations with CHD at the census tract level. The study obtained 0.53 million GSV images covering 789 census tracts in seven US cities (Cleveland, OH; Fremont, CA; Kansas City, MO; Detroit, MI; Bellevue, WA; Brownsville, TX; and Denver, CO).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Built environment features extracted from GSV using deep learning predicted 63% of the census tract variation in CHD prevalence. The addition of GSV features improved a model that only included census tract-level age, sex, race, income, and education or composite indices of social determinant of health. Activation maps from the features revealed a set of neighbourhood features represented by buildings and roads associated with CHD prevalence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38544295</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae158>10.1093/eurheartj/ehae158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544295</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Yassin Khalifa</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</dc:title>
<dc:identifier>pmid:38544295</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae158</dc:identifier>
</item>
<item>
<title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae159. doi: 10.1093/eurheartj/ehae159. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38544282</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae159>10.1093/eurheartj/ehae159</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544282</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</dc:title>
<dc:identifier>pmid:38544282</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae159</dc:identifier>
</item>
<item>
<title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240330021025&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):e129. doi: 10.1016/j.jacc.2024.01.032. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240330021025&v=2.18.0.post9+e462414">38538207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.032>10.1016/j.jacc.2024.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538207</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>R Scott Wright</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</dc:title>
<dc:identifier>pmid:38538207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.032</dc:identifier>
</item>





























</channel>
</rss>